Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated hospitalization rates among infants aged 0 to 7 months during the 2024 ...

Nirsevimab associated with lower odds of RSV-related hospitalization, ICU admission, lower respiratory tract infection incidence. HealthDay News — Nirsevimab is effective for reducing the burden ...

Among 69 hospitalisations of infants for respiratory syncytial virus (RSV)–related lower respiratory tract infection (LRTI) in a Spanish study, 65.2% occurred despite the administration of ...

Colored scanning electron micrograph (SEM) of a macrophage white blood cell (center) that is being destroyed by toxins released by E. coli bacteria (red). Some strains of E. coli release ...

Respiratory syncytial virus (RSV)–associated hospitalization rates among infants in the United States were significantly lower in the first year when prevention products were widely available ...

Last winter’s respiratory syncytial virus, or RSV, season wasn’t as brutal for U.S. babies. A new study suggests two preventive tools — a maternal vaccine and a monoclonal antibody for ...

THURSDAY, May 8, 2025 (HealthDay News) -- Nirsevimab is effective for reducing the burden of respiratory syncytial virus (RSV) in infants in real-world settings, according to a study published ...

but a decline is anticipated soon in an infection that most commonly afflicts children — respiratory syncytial virus, the Pima County Health Department says. The infection commonly referred to ...

HMPV is a relatively recent discovery in human respiratory viruses and, like Respiratory Syncytial Virus (RSV), can cause conditions ranging from asymptomatic infection to severe bronchiolitis.

RSV prevention products led to a significant reduction in hospitalization rates for infants aged 0 to 7 months during the 2024-2025 season. The maternal RSV vaccine and nirsevimab were key ...